• UPDATE : 2020.2.28 금 07:31
상단여백
기사 (전체 86건)
Takeda Named Global Top 100 Most Sustainable Corporation for Fifth Year Running
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) is p...
라인
Approval for Aservo? EquiHaler?, industry first therapy for severe equine asthma
Horses with severe equine asthma struggle to breath, even at rest. Last wee...
라인
Takeda to Outline Progress on Business Transformation and Priorities at the 38th Annual J.P. Morgan Healthcare Conference
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) will...
라인
대웅제약 'DWP14012정' 미란성 위식도역류질환 완치 환자서 유지요법으로 DWP14012 투여 시 '유효성·안전성' 평가…한국MSD 'MK-6482' 3상· 한국유나이티드제약 'UI063' 3상·한국노바티스 'AIN457' 3상 임상승인
한국MSD(한국엠에스디) 'MK-6482'의 경우, 과거 PD-1/L1 및 VEGF 표적 요법 이후 질병진행을 경험한 진...
라인
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), toda...
라인
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limi...
라인
Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene(ASTMH) 68th Annual Meeting
Takeda Pharmaceutical Company Limited (TSE:4502 / NYSE:TAK) (“Takeda”) toda...
라인
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will h...
라인
Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
A new interim analysis of three-year data from the EMPagliflozin compaRativ...
라인
GSK, 라이엘 이뮤노파마와 '차세대 항암 세포치료제 개발' 제휴…GSK 세포치료제 파이프라인 '라이엘 기술 적용' 한층 강화 전망
GSK(한국법인 대표 줄리엔 샘슨)는 암 환자를 위한 세포치료제를 개선할 신기술 개발을 위해 샌프란시스코 소재의 생명공학기업인 라이엘 ...
라인
제브 웨인버그 박사 "의료진들 특히 1차 치료서 '췌장암 환자 위한 더 많은 치료 옵션 보유' 매우 중요"…세르비에·입센 '전이성 췌장암 1차 치료로서 오니바이드 초기 1/2상 연구 결과' 발표
세르비에(Servier)와 입센(Ipsen)은 지난 7월 3일부터 6일까지 스페인 바르셀로나에서 개최된 유럽종양학회(ESMO) 제 21...
라인
'GSK 美 항암제 개발사 테사로 인수' GSK R&D 사장 할 바론 박사 "GSK '항암제 파이프라인 한층 강화'…더 많은 암 환자들에게 더 빠르게 도움 줄 수 있는 '새로운 과학적 역량·전문성' 갖추게 됐다"
GSK는 현금가치 약 51억 달러(한화 약 5조 8천억 원)에 미국 매사추세츠주 소재의 종양학 전문 바이오 제약사인 테사로(TESARO...
라인
Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders
Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery ...
라인
Takeda Completes Acquisition of Shire, Becoming a Global, Values-Based, R&D-Driven Biopharmaceutical Leader
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) to...
라인
Multiple Cell Therapy Collaborations to Advance the Company’s Novel Immuno-Oncology Portfolio
Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) today announce...
라인
Vargatef plus docetaxel could be an option after failure of immunotherapy in lung cancer
Boehringer Ingelheim announced today the first interim results of VARGADO, ...
라인
Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting
Takeda Pharmaceutical Company Limited (TSE:4502) today announced that data ...
라인
European Commission Approves ALUNBRIG for ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib, Advancing Treatment Paradigm in Europe
Takeda Pharmaceutical Company Limited(TSE: 4502) announced that the Europea...
라인
Sanofi Appoints Eun-Ju Kim as Head of HR in Korea
Nov. 27, 2018, Seoul –Sanofi-aventis Korea(County Chair: kay Bay, her...
라인
Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for Blood Cancers
Takeda Pharmaceutical Company Limited (TSE: 4502) announced that it will pr...
-12345-
Back to Top